A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Valganciclovir (Valcyte) in Patients Experiencing Chronic Fatigue Syndrome With Elevated Antibody Titers Against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV)
Latest Information Update: 30 May 2022
At a glance
- Drugs Valganciclovir (Primary)
- Indications Chronic fatigue syndrome; Epstein-Barr virus infections; Herpesvirus infections
- Focus Therapeutic Use
- Acronyms EVOLVE
- 23 May 2022 Status changed from active, no longer recruiting to completed.
- 30 Aug 2007 Status changed from recruiting to in progress.
- 25 Jul 2007 New trial record.